EPS for Arena Pharmaceuticals, Inc. (ARNA) Expected At $-0.70

April 22, 2018 - By Max Morgan

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Logo

Analysts expect Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to report $-0.70 EPS on May, 8.They anticipate $0.20 EPS change or 22.22 % from last quarter’s $-0.9 EPS. After having $-0.36 EPS previously, Arena Pharmaceuticals, Inc.’s analysts see 94.44 % EPS growth. The stock increased 1.07% or $0.42 during the last trading session, reaching $39.69. About 716,391 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has risen 169.40% since April 22, 2017 and is uptrending. It has outperformed by 157.85% the S&P500.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Ratings Coverage

Among 7 analysts covering Arena Pharma (NASDAQ:ARNA), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Arena Pharma had 14 analyst reports since November 8, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Monday, February 26 by Cantor Fitzgerald. The firm has “Buy” rating given on Tuesday, March 20 by Needham. The company was maintained on Tuesday, March 20 by Cantor Fitzgerald. Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Wednesday, March 14 with “Buy” rating. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, November 8. Wells Fargo upgraded the shares of ARNA in report on Wednesday, January 3 to “Outperform” rating. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, January 4. The rating was maintained by Citigroup on Tuesday, February 27 with “Buy”. Cantor Fitzgerald maintained the shares of ARNA in report on Wednesday, April 18 with “Buy” rating. Wells Fargo maintained the shares of ARNA in report on Tuesday, March 20 with “Buy” rating.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $1.95 billion. The company's proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.